INSIGHT: Epstein-Barr Virus is a Risk Factor for MS | MS Canada EBV infection increased risk of MS by 32-fold This study suggests that EBV acts as an initial trigger or pre-condition required for MS onset (6) While EBV is likely necessary, it is not sufficient to trigger MS, and it is believed that other factors are needed For more details, read this article
The role of Epstein-Barr virus in multiple sclerosis: from molecular . . . This review evaluates the role of EBV in MS from both clinical and imaging point of view, explores the effects of disease-modifying therapies that might be targeting EBV, and discusses other emerging virus candidates that may be potentially involved in MS pathogenesis
Epstein-Barr Virus Infection Promotes Autoimmunity in Multiple . . . In a study published in Science Advances, a team of scientists at UBC and the Fraser Health Multiple Sclerosis Clinic provide new evidence that latent infection with Epstein-Barr virus can prime the immune system for susceptibility to multiple sclerosis (MS)
MINI-review of Epstein-Barr virus involvement in multiple sclerosis . . . EBV is a ubiquitous herpesvirus that establishes a lifelong infection in the human host There is now compelling evidence that EBV infection is an essential and early factor in MS development B cells are the main reservoir for EBV latent infection and have a key role in MS pathogenesis
Novel preclinical humanized mouse models of MS the in’s and out’s of . . . Epstein-Barr virus (EBV) is a risk factor for MS This research will support the development and use of a mouse model that can be infected with EBV and used to explore MS disease initiation and progression of MS disease subtypes (i e relapsing-remitting MS and primary progressive MS)
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging . . . The idea that a virus may play a role in the development of MS has a long history and is supported mostly by studies demonstrating a link between B cell-tropic Epstein–Barr virus (EBV) and disease onset Efforts to develop antiviral strategies for treating MS are underway